Jasper Therapeutics, Inc. (NASDAQ:JSPRW) Short Interest Up 34.6% in August

Jasper Therapeutics, Inc. (NASDAQ:JSPRW) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totalling 21,400 shares, an increase of 34.6% from the August 15th total of 15,900 shares. Based on an average daily trading volume, of 4,300 shares, the days-to-cover ratio is currently 5.0 days.

Jasper Therapeutics Stock Up 6.7 %

JSPRW traded up $0.01 during trading on Monday, reaching $0.20. The stock had a trading volume of 5,355 shares, compared to its average volume of 20,300. The business has a 50-day moving average of $0.21 and a 200-day moving average of $0.20. Jasper Therapeutics has a one year low of $0.04 and a one year high of $0.38.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.